Skip to Content

Novartis AG ADR NVS

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Novartis Posts Soft 1Q, Hurt by Tough Comparisons and Generic Pressures, but Key Drugs Track Well

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

Novartis reported soft growth in the first quarter as the prior-year quarter benefited from stocking due to the COVID-19 pandemic. However, we don’t expect any changes to our fair value estimate based on the minor weakness in the results, and the stock looks moderately undervalued. Further, the firm continues to innovate well with several new drugs posting solid launches, reinforcing our wide moat rating for the firm.

Read Full Analysis

Company Profile

Business Description

Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Contact
Lichtstrasse 35
Basel, 4056, Switzerland
T +41 613241111
Sector Healthcare
Industry Drug Manufacturers - General
Most Recent Earnings Mar 31, 2021
Fiscal Year End Dec 31, 2021
Stock Type
Employees 110,000

Related